Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295938 | 0.85 | LMNA (0.35) | LMNACES2MEN1USP2POLB | |
| SCHEMBL3322492 | 0.76 | HTT (0.33) | LMNAMEN1USP2POLBMAPT | |
| SCHEMBL11820163 | 0.75 | — | — | |
| SCHEMBL11456012 | 0.74 | CHRM3 (0.35) | LMNAMEN1USP2POLBMAPT | |
| SCHEMBL11815642 | 0.71 | OPRM1 (0.33) | LMNAMEN1USP2POLBMAPT | |
| SCHEMBL11810265 | 0.71 | CHRM3 (0.34) | LMNAMEN1USP2POLBMAPT | |
| SCHEMBL11107808 | 0.71 | MEN1 (0.31) | LMNAMEN1USP2POLBMAPT | |
| SCHEMBL11459614 | 0.70 | CHRM3 (0.36) | LMNAMEN1USP2POLBMAPT | |
| SCHEMBL11468000 | 0.70 | MEN1 (0.33) | LMNAMEN1USP2POLBMAPT | |
| SCHEMBL11449531 | 0.70 | MEN1 (0.33) | LMNAMEN1USP2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739066-B2 | Method for fluoroalkylation of enamines | ARXADA AG (CH) | 2023-08-29 | — | — | US | disclosed |
| US-11739066-B2 | Method for fluoroalkylation of enamines | ARXADA AG (CH) | 2023-08-29 | — | — | US | disclosed |
| US-20220204464-A1 | Method for Fluoroalkylation of Enamines | LONZA LTD (CH) | 2022-06-30 | — | — | US | disclosed |
| WO-2020249759-A1 | METHOD FOR FLUOROALKYLATION OF ENAMINES | LONZA LTD (CH) | 2020-12-17 | — | — | WO | disclosed |
| EP-2970118-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | MANFREDI JOHN (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2970118-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Manfredi, John (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2007115306-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115306-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1809601-A2 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYRIAD GENETICS, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006041874-A2 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYRIAD GENETICS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| US-4478837-A | HYPOTENSIVE AGENTS | SANDOZ LTD. (CH) | 1984-10-23 | — | — | US | disclosed |
| US-3997557-A | ANTIARRHYTHMIA, CNS DEPRESSANT, ANTIINFLAMMATORY, HYPOTENSIVE | AMERICAN HOECHST CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
| US-3954754-A | ANTIHYPERTENSIVES | SANDOZ LTD. (CH) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | LMNA 35/4885CES2 1570/4885MEN1 3473/4885 |
| US-11739066-B2 | Method for fluoroalkylation of enamines | HNMT, PNMT, INMT | LMNA 1971/4885CES2 79/4885MEN1 1505/4885 |
| US-20220204464-A1 | Method for Fluoroalkylation of Enamines | HNMT, PNMT, INMT | LMNA 1971/4885CES2 79/4885MEN1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.